China: Study on Diabetic Nephropathy Treatment

A recent study published in International Immunopharmacology by Yinyu Wei and colleagues showcases the efficacy of a combination of nifedipine controlled-release tablets and sacubitril valsartan in patients with diabetic nephropathy (DN) accompanied by hypertension. With over a hundred participants, this prospective randomized controlled study aims to shed light on a potential treatment approach for this often intricate health concern.

The study enrolled 112 participants with a history of type 2 diabetes mellitus (T2DM) exceeding six years. Randomly divided into two groups, the participants underwent different treatment regimens:

• One group received nifedipine-controlled-release tablets combined with valsartan.
• The other group received nifedipine-controlled-release tablets combined with sacubitril valsartan.

The results showcased that after a three-month treatment period, the observation group (nifedipine controlled-release tablets combined with sacubitril valsartan) exhibited significantly lower levels of various clinical indices, renal function indicators, endothelial function indicators, and inflammatory response factors compared to the control group.

Glycosylated haemoglobin, fasting blood glucose, systolic and diastolic blood pressure, and other key parameters experienced a reduction in the observation group.

Diabetic nephropathy is a frequent complication of type 2 diabetes, often aggravated by hypertension. In this study, the combination of nifedipine and sacubitril valsartan proved to be promising in addressing the intricate health concerns associated with these conditions. The treatment showcased improvements in renal and endothelial function, reducing inflammation and positively influencing clinical indicators.

The study's outcomes indicate that the combination of nifedipine controlled-release tablets and sacubitril valsartan presents a potential avenue to alleviate the progression of diabetic nephropathy in the presence of hypertension. With favourable outcomes and minimal adverse effects, this approach offers a glimpse of hope for individuals grappling with these complex health issues. As researchers delve deeper into this treatment approach, further investigations and clinical trials are warranted to validate its efficacy and safety.

Reference

Wei, Y., Hu, L., & Liu, G. (2023). Therapeutic improvements of nifedipine controlled-release tablets combined with sacubitril valsartan on patients with diabetic nephropathy complicated with hypertension. International Immunopharmacology, 123(110755), 110755. https://doi.org/10.1016/j.intimp.2023.110755